Skip to main content
949-645-2250 Request Appointment

DR. ARTHUR ASTORINO CERTIFIED TO INSTALL THE FIRST AND ONLY FDA-APPROVED TRIFOCAL LENS [PANOPTIX]

Astorino & Associates Eye Center Blog DR. ARTHUR ASTORINO CERTIFIED TO INSTALL THE FIRST AND ONLY FDA-APPROVED TRIFOCAL LENS [PANOPTIX]
Alcon Introduces AcrySof IQ PanOptix Trifocal IOL in the U.S., the First and Only FDA-Approved Trifocal Lens!

Dr. Arthur Astorino, Jr. among the first providers to become certified.
​
  • PanOptix delivers an exceptional combination of near, intermediate and distance vision and substantially reduces the need for glasses (1,2)
  • More than ninety-nine percent of PanOptix patients in the FDA clinical study said they would choose the same lens again(1)​

​Geneva, August 27, 2019 – Alcon (SIX/NYSE:ALC), the global leader in eye care, today announced the Food and Drug Administration (FDA) approval and its initial commercial launch of AcrySof®IQ PanOptix®Trifocal Intraocular Lens (IOL), the first and only trifocal lens for U.S. patients undergoing cataract surgery. PanOptix is clinically shown to deliver an exceptional combination of near, intermediate and distance vision while significantly reducing the need for glasses after surgery.(1,2)

PanOptix is already one of the leading presbyopia-correcting IOLs in more than 70 countries. It is designed for today’s active lifestyles, from viewing mobile devices and computer screens to high-quality distance vision in a range of lighting conditions. The new lens uses ENLIGHTEN®Optical Technology, a proprietary design that optimizes intermediate vision without compromising near and distance vision. Available in spherical and toric designs, PanOptix is built on Alcon’s proven AcrySof IQ IOL platform that has been implanted in more than 120 million eyes globally.

More than 4 million cataract surgeries are performed each year in the U.S., which is projected to increase by more than 16 percent by the end of 2024. (3,4) The presbyopia-correcting IOL market is expected to grow 60 percent by the end of 2024. (4)
“The U.S. ophthalmology community has been eagerly awaiting FDA approval of PanOptix. While participating in the clinical trial, I saw first-hand the impact of this lens on my patients,” said Kerry Solomon, M.D., Carolina Eyecare Physicians,PanOptix clinical trial investigator. “We know patients undergoing cataract surgery today want a replacement lens that delivers the vision they need to live full, active lives without always being dependent on glasses. PanOptix is an excellent lens option to address these needs and is clinically proven to deliver an outstanding range of vision.”

References
  1. AcrySof®IQ PanOptix®Directions For Use.
  2. Compared to AcrySof®monofocal IOL.
  3. Market Scope. 2017 Ophthalmic Surgical Instrument Report.
  4. Market Scope. 2019 IOL Market Report. April 2019.
Author
Dr. Arthur Astorino, JR. MD Arthur Astorino, Jr., MD, is a board-certified ophthalmologist who has been practicing since 1988. He provides exceptional eye care to his patients at Astorino & Associates Eye Center in Newport Beach, California, in areas like general ophthalmology, advanced cataract care, and refractive surgery.

You Might Also Enjoy...

We Offer Optos Retinal Imaging
Experience enhanced eye care with Optos imaging technology at our clinic. Our advanced evaluations detect diabetes, macular degeneration, melanoma, bleeding, hypertensive retinopathy, and glaucoma early, preventing vision loss.